The (À938C4A) polymorphism in the promoter region of the BCL-2 gene was recently associated with inferior time to treatment and overall survival in B-cell chronic lymphocytic leukemia (CLL) patients displaying the À938A/A genotype and may thus serve as an unfavorable genetic marker in CLL. Furthermore, the À938A/A genotype was associated with increased expression of Bcl-2. To investigate this further, we analyzed the À938 genotypes of the BCL-2 gene in 268 CLL patients and correlated data with treatment status, overall survival and known prognostic factors, for example, Binet stage, immunoglobulin heavy-chain variable (IGHV) mutational status and CD38 expression. In contrast to the recent report, the current cohort of CLL patients showed no differences either in time to treatment or overall survival in relation to usage of a particular genotype. In addition, no correlation was evident between the (À938C4A) genotypes and IGHV mutational status, Binet stage or CD38. Furthermore, the polymorphism did not appear to affect the Bcl-2 expression at the RNA level. Taken together, our data do not support the use of the (À938C4A) BCL-2 polymorphism as a prognostic marker in CLL and argue against its postulated role in modulating Bcl-2 levels.
Introduction
B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in the western world. 1 The disease is characterized by continual accumulation of CD5 þ /CD23 þ B cells in the peripheral blood, bone marrow, lymph nodes and spleen, where the neoplastic B cells are halted in G0 and/or early G1 phase and are unable to undergo apoptosis. 2, 3 CLL is a clinically heterogeneous disease in which many patients require little or no treatment for many years, whereas others progress rapidly and succumb to the disease even with treatment. So far, no single predisposing genetic factor has been convincingly identified in all CLL cases. At present, the Rai 4 and Binet 5 clinical staging systems, which stratify patients based on disease burden and the degree of bone marrow involvement, is the standard prognostic tool in clinical practice. However, these staging systems are not optimal in predicting progression at an early stage of the disease. During recent years, several new molecular markers that can predict outcome have been demonstrated in CLL, such as genomic aberrations, 6 the somatic hypermutation status of the immunoglobulin heavy-chain variable (IGHV) genes, 7, 8 the expression of the surface protein CD38 7 and intracellular expression of ZAP-70. 9 Recently, single-nucleotide polymorphisms (SNPs) within certain genes (BAX, P2X7, GNAS1 and MCL-1) have also been associated with disease progression and clinical outcome, although none of these studies has been confirmed in subsequent studies from other centers. [10] [11] [12] [13] [14] [15] [16] [17] Bcl-2 belongs to a growing family of apoptosis-regulatory gene products, comprising both proapoptotic (Bax, Bak, Bcl-X S , Bad, Bid, Bik and Hrk) and antiapoptotic (Bcl-2, Bcl-X L , Bcl-W, Brag-1, Mcl-1 and Bfl-1/A1) members. 18, 19 CLL cells have been shown to display dysregulated apoptosis with high expression of the Bcl-2 protein in most cases. 20 The Bcl-2 expression level may also correlate with clinical outcome, since high Bcl-2 expression was associated with poor prognosis. 21 Furthermore, a high ratio between the Bcl-2 protein and Bax protein has been associated with resistance to apoptosis in vitro. 22 The BCL-2 gene, located on chromosome 18q21.3 and consisting of three exons and two promoters, 23 was originally identified in t(14;18)(q32;q21)-positive B-cell lymphomas. 24 The first promoter, P1, enhances the expression of the BCL-2 gene, while the second promoter, P2, dampens the activity of P1 and thus, serves as a negative modulator of Bcl-2 expression. 25 Recently, an SNP (À938C4A) in the P2 position of BCL-2 gene was reported to serve as a predictor for disease progression and overall survival in CLL. 26 The investigators showed that CLL patients with the À938A/A genotype had shorter median overall survival and median time from first diagnosis to initiation of chemotherapy compared with those with À938AC/CC genotypes. The À938A/A genotype was also indicated as an independent prognostic factor for progression-free survival in CLL. Furthermore, CLL patients with the À938A/A genotype demonstrated increased Bcl-2 expression levels, indicating a mechanistic link between the A/A genotype and worse outcome.
The aim of this study was to further investigate the role of the BCL-2 (À938C4A) polymorphism in CLL. Here, we analyzed 268 CLL cases for this polymorphism and correlated genotypes with clinical data and known prognostic markers (for example, Binet stage, IGHV mutational status and CD38 expression). We also studied BCL-2 expression at the RNA level between the different genotypes.
Materials and methods

Patients and materials
Our study cohort consisted of 268 Swedish and Finnish CLL cases, which were enrolled at several University hospitals in both countries. CLL cells typically expressed CD5, CD23 and a low expression of surface Ig, according to the WHO classification. 27 Tumor samples were identified from the archives of frozen tissue specimens at the Biobanks of the University Hospitals of Uppsala (n ¼ 117), Huddinge (n ¼ 18), Linköping (n ¼ 51), Umeå (n ¼ 53), Sweden and Tampere (n ¼ 29), Finland. Frozen tumor material was obtained predominantly from peripheral blood and bone marrow; however, a number of samples were obtained from other sources such as lymph nodes and spleen. Overall survival data were available on all 268 patients, with a median follow-up time of 95 months (quartile range: 51-148 months), while data on time to treatment was available for 117 patients. Binet stage data were available in 218 patients.
Analysis of the BCL-2 (À938C4A) promoter polymorphism
Genomic DNA was extracted from frozen tumor cells as described previously.
11 DNA was whole-genome amplified according to the manufacturer's protocol (GenomiPhi DNA Amplification, GE Healthcare, Uppsala, Sweden). For genotyping, information on PCR and minisequencing primers was collected from the SNP assay database (http://las.perkinelmer.com/content/forms/SNPDatabase/ welcome.asp). Genotyping was performed using single-base primer extension with detection by fluorescence polarization (SBE-FP) 28 using reagents from Perkin Elmer (Waltham, MA, USA). The accuracy was 99% according to duplicate analysis of 66% of the genotypes. Comparison of the BCL-2 (À938C4A) genotypes in 20 individuals from whole-genome amplified DNA and genomic DNA from the same individuals showed identical results.
Assessment of IGHV gene mutational status
The IGHV gene mutational status was assessed by PCR amplification with IGHV gene family-specific primers, followed by sequence analysis as described previously or according to the BIOMED-2 protocol. 29, 30 Sequences were thereafter aligned in the GenBank/IgBLAST, IMGT and V-BASE online databases to determine the germline IGHV homology. The IGHV gene was considered unmutated when the homology to the germline gene was greater than 98%.
CD38 expression
CD38 was analyzed by flow cytometry as described previously. 31 A 20% CD38 cutoff was used to define CD38-positive/-negative samples.
MLPA analysis
The expression level of BCL-2 RNA was measured in 45 CLL patient samples using multiplex ligation-dependent probe amplification (MLPA). RNA was extracted using the mini prep kit (Qiagen GmbH, Hilden, Germany) and concentrations measured utilizing the NanoDrop instrument (NanoDrop Technologies Inc., Wilmington, DE, USA). The quality of RNA was controlled using the Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany). MLPA RNA analysis was carried out using the SALSA RT-MLPA KIT R011 Apoptosis mRNA as per the manufacture's instruction (MRC Holland, Amsterdam, The Netherlands). Briefly, 100 ng of RNA was reverse transcribed using the Moloney Murine Leukemia Virus reverse transcriptase (Invitrogen AB, Stockholm, Sweden) and gene specific primers (Invitrogen AB, Sweden) for 35 apoptosis-related genes and 4 control genes in a single multiplex reaction. MLPA probes were subsequently added and allowed to hybridize for 16 h at 60 1C. After hybridization, the probes were ligated with ligase 65 followed by PCR amplification utilizing FAM-labeled M13 primers. All PCR products were analyzed on the Applied Biosystems (Foster City, CA, USA), 9700 electrophoresis DNA sequencer using GeneScan software (version 3.7.1). Peak tables for each sample were exported from GeneScan to Microsoft Excel where data was normalized to the control gene b2-microglobulin.
Statistical analysis
All statistical analyses in the current study were carried out with Statistica version 7 (Stat Soft Inc., Tulsa, OK, USA). Fisher's exact test or w 2 -test were employed to determine the significance of differences in genotype use between patient groups. Comparison of median age at diagnosis between patients with different genotypes was carried out using the Kruskal-Wallis test. Kaplan-Meier analysis was performed for overall survival and treatment-free survival. Differences in duration of time to treatment and overall survival between groups were evaluated using the log-rank test. Overall survival was calculated from the date of diagnosis until the last follow-up or death. Time to treatment was defined as time from diagnosis until initial treatment.
Results
The BCL-2 (À938C4A) genotype distribution
The BCL-2 (À938C4A) genotype distribution in our cohort was in accordance with the Hardy-Weinberg equilibrium and was comparable to the recently published study. 26 Of the 268 CLL samples investigated, 122 (46%) displayed a heterozygous genotype for the BCL-2 (À938C4A) polymorphism, while 89 (33%) and 57 (21%) of the patients were homozygous for the A/A and C/C genotype, respectively. There was no difference in median age of diagnosis between the three groups; 63, 65 and 67 years in patients with À938A/A, À938A/C and À938C/C genotypes, respectively.
The BCL-2 (À938C4A) polymorphism and survival No significant difference in overall survival was evident between patients with the different BCL-2 (À938C4A) genotypes (Figure 1 ). The median survival was 81 months (range: 48-136 months), 102 months (range: 52-149 months) and 107 months (range: 61-137 months) for patients with the À938A/A, À938A/C and À938C/C genotypes, respectively. Dichotomizing by dividing the BCL-2 (À938C4A) genotypes as C þ genotypes (combining the C/C and A/C genotypes as one group) and CÀ genotype (A/A) also failed to indicate any significant difference in patients' overall survival between the groups (Figure 2) . Furthermore, our Kaplan-Meier analysis did not reveal any significant differences in time to treatment between CLL cases with A/A, A/C and C/C genotypes when examined individually (Figure 3) . Similarly, no significant difference was observed when the genotypes were dichotomized as C þ and CÀ genotypes (Figure 4 ).
The BCL-2 (À938C4A) polymorphism and relation to known prognostic markers IGHV gene mutation analysis revealed that 115 (43%) cases carried mutated IGHV genes, while 153 (57%) cases showed unmutated IGHV genes. In line with previous reports, 7, 32 patients with unmutated IGHV genes had a significantly shorter (72 months, range: 40-117 months) median overall survival than patients with mutated IGHV genes (125 months, range: 74-190 months, Po0.0001). One hundred and twenty-six patients were classified as Binet stage A, 56 as stage B and 36 as stage C. As expected, Binet stage A patients had a longer median survival (142 months, range: 65-212 months) than stage B patients (75 months, range: 51-110 months) and stage C patients (51 months, range: 36-110 months). Out of 103 patients, 49 were defined as CD38-positive and the remaining CD38 negative. In parallel to earlier reports, 7,32-34 CD38-positive patients had shorter median overall survival (69 months, range: 39-103 months, P ¼ 0.007) compared to CD38-negative patients (114 months, range: 51.8-148 months).
Overall, no significant difference was found in genotype distribution in relation to Binet stage and IGHV mutation status (Table 1) . It was noted that the proportion of A/C genotype was higher among CD38-negative patients as compared to A/A and C/C genotypes. However, the relevance of this finding is unknown, if any. With regard to the overall survival analysis, combination of IGHV mutation status and À938 genotype data showed no significant difference in survival when investigating the IGHVmutated or the unmutated subgroups with or without the polymorphism. A similar finding was observed with the time to treatment interval among IGHV-mutated/unmutated cases. Furthermore, univariate Cox regression analysis indicated only IGHV mutational status and CD38 as the significant prognostic indicators.
BCL-2 RNA expression
Among the 45 CLL cases from which the BCL-2 RNA expression were measured by MLPA, 17 of them displayed the À938 A/C genotype, while 9 and 19 cases were homozygous for C/C and A/A genotypes, respectively. Analysis of the BCL-2 expression level between patients with the different genotypes showed no significant difference ( Figure 5 ).
Discussion
The BCL-2 (À938C4A) polymorphism was originally identified by Park and colleagues, 35 in a study to characterize different Figure 2 Overall survival for CLL patients dichotomized into C þ alleles (A/C þ C/C) and CÀ alleles (A/A) (P ¼ 0.368, log-rank test). CLL, chronic lymphocytic leukemia. Figure 1 Overall survival for CLL patients according to the BCL-2 (À938C4A) polymorphism status. No significant difference was indicated by log-rank test between the any of the genotypes indicated. CLL, chronic lymphocytic leukemia.
BCL-2 polymorphism in CLL MA Kaderi et al variants in the cyclin D1 (CCND1) and BCL-2 genes. This polymorphism was found on the second promoter, P2, of the BCL-2 gene, which was characterized as a negative modulator of the first promoter, P1, and subsequently, BCL-2 gene expression. 25 A recent work by Nuckel et al. 26 reported that the presence of the À938A/A genotype was associated with decreased activity of the P2 and increased Bcl-2 protein expression in CLL. These authors also suggested the BCL-2 (À938C4A) polymorphism as a novel prognostic marker in CLL, since they reported a significantly worse median overall survival and progressive-free survival in CLL patients carrying the A/A genotype as compared to patients with C þ alleles.
In contrast, in our CLL material, no significant difference was shown in overall survival between patients with the À938 A/A vs A/C or C/C genotypes. It should be noted that our study cohort consists of a higher proportion of Binet stage B and C cases and cases carrying unmutated IGHV rearrangements. Thus, our cohort seems to have more aggressive clinical course than in the study by Nuckel et al. 26 That notwithstanding, similar findings were observed when only stage A and mutated cases were analyzed. Furthermore, when the BCL-2 genotype status was combined with IGHV mutation data, no significant difference in overall survival was evident within either the IGHV-mutated or unmutated subgroups. Also contrary to the study by Nuckel et al., 26 we did not find any significant difference in the length of the progression-free interval as indicated by time from diagnosis to the first treatment in our CLL cohort. Moreover, there was no indication that the BCL-2 polymorphism affects disease progression in CLL patients within any specific Binet stage or within mutated/unmutated subgroups. Thus, our findings clearly argue against the notion that the BCL-2 (À938A/A) genotype could serve as an independent prognostic factor for time to first treatment.
Nuckel et al. 26 also demonstrated that the BCL-2 À938A/A genotype was associated with increased Bcl-2 expression, which would point to a pathogenetic role of this polymorphism in CLL. Our study, however, did not find any significant difference in RNA expression level between CLL samples displaying the various BCL-2 (À938C4A) genotypes, which implies that the effects of the BCL-2 polymorphism on Bcl-2 expression in our material were limited. However, the possibility still exists that the increased Bcl-2 protein levels in CLL cases with the À938A/A genotype reported in the earlier study may be caused by post-translational modification.
In summary, the current study shows that the clinical impact of the BCL2 polymorphism in CLL is limited, since the presence of the BCL-2 (À938C4A) polymorphism did not significantly affect either patients' disease progression or overall survival. The polymorphism also did not correlate with either the expression level of the BCL-2 gene or with known prognostic markers in this large series of 268 CLL patients. Table 1 Clinical data of the current cohort of CLL cases genotyped for the BCL-2 (À938C4A) polymorphism Jansson and Lesley Sutton for their technical advice and assistance in this study.
